the generic version of the wonder drug Daclatasvir for treatment of Hepatitis C under the brand name of Daclavir.
Recommended Dosage: The recommended dosage of Daclavir is 60
mg, taken orally, once daily in combination with Sofosbuvir for 12
weeks. Daclavir may be taken with or without food. The optimal
duration of Daclavir and Sofosbuvir for patients with cirrhosis has
not been established.
Risk of Adverse Reactions or Loss of Virologic Response Due to Drug
Interactions: The concomitant use of Daclavir and other drugs may
result in known or potentially significant drug interactions,some of
which may lead to
1. Loss of therapeutic effect of Daclavir and possible
2. development of resistance
Dosage adjustments of concomitant medications or Daclavir
3. Possible clinically significant adverse reactions from greater
exposures of concomitant drugs or Daclavir
The following serious adverse reactions are described below
Serious Symptomatic Bradycardia When Co-administered with
Sofosbuvir and Amiodarone.
In the ALLY-3 trial, 152 treatment-naive and treatment-experienced
subjects with HCV genotype 3 infection were treated with
Daclatasvir 60 mg once daily in combination with Sofosbuvir for 12
weeks. The most common adverse reactions (frequency of 10% or
greater) were headache and fatigue.